ADMA logo

ADMA BIOLOGICS INC

ADMANASDAQ
🏆 #1877 by market capUS Equity
$674.28▼ $40.05 (−5.94%)
Simulated price
🔔
Track ADMA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.9%
7d▲ 6854.9%
14d▲ 7463.4%
30d▲ 7088.5%
ytd▲ 3598.7%
1y▲ 4501.0%
🏦Market Cap
$2.35B
Small Cap
📈Revenue Growth (YoY)
+19.6%
Healthy
📊Gross Margin
64.7%
High
💵FCF Margin
22.7%
Strong
⚖️P/S Ratio
4.6x
Fair
Otter Score
80
Good

Trading Snapshot

Day Range
$665.49 – $684.03
52-Week Range
$7.21 – $20.46
Volume
$4.85B
Avg Volume
$5.79B
Shares Outstanding
231.8M
Next Earnings
Dec 6, 2026

Fundamentals Snapshot

Annual Revenue
$510M
Last Q Revenue
$124M
P/E Ratio
14.1
P/S Ratio
4.6x
EPS (TTM)
$0.74
Dividend Yield
0.00%
Dilution (1yr)
−0.8%

Why Investors Own ADMA

  • ✓High-growth profile — revenue up -4.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 74% gross margin and 10% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ADMA logo

ADMA BIOLOGICS INC

ADMA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$510M▲ +19.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
57.4%▲ +11.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$191M▲ +37.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$28M▼ −74.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
243.9M▼ −0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▼ −$13M YoY
StockOtter · stockotter.space

About ADMA BIOLOGICS INC

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Price Target

ⓘ
Average Target
$701.34
▲ +4.0% Upside
High Target$813.22
Low Target$653.51
Based on 22 analysts

Latest News & Updates

🚀
Reuters·2h ago

ADMA BIOLOGICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift ADMA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ADMA BIOLOGICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.